Ulcerative Colitis, Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Conditions
Keywords
Ulcerative colitis, Diet, Partial enteral nutrition, Microbiome
Brief summary
The ReDUCE Trial is a multinational single-blinded randomized controlled trial in mild to moderate flare of Ulcerative colitis (UC) disease patients. The purpose of the study is to validate the clinical efficacy of the UCED (Ulcerative colitis Exclusion Diet) with partial enteral nutrition (PEN) using a novel formula. The investigators anticipate that adding a novel specifically designed dietary intervention in addition to drug will lead to superior remission and mucosal healing via changes in the microbiome.
Detailed description
Rational: Ulcerative colitis is currently treated only by medical therapies or surgery and there is no other option to avoid immune suppression. Thus, developing a dietary therapy that would treat the cause of the disease, while having no side effects, would likely lead to immediate implementation and be sought out by patients hesitant to be on lifelong medications or immune suppression. Objectives: To evaluate if the UC Exclusion Diet (UCED), can improve outcomes when administered with an oral budesonide regimen to adult patients with mild to moderate UC. Methods: This will be a 24-week multinational single-blinded randomized controlled trial. After a baseline flexible sigmoidoscopy, Group 1 will receive oral budesonide 9 mg topical therapy + the UCED+PEN phase 1 diet for 6 weeks, while Group 2 will receive oral budesonide 9 mg topical therapy alone for 6 weeks with no dietary intervention. Both groups will continue the previous maintenance therapy through week 12 and both groups will stop budesonide at week 6. Group 1 will continue with the phase 2 diet/PEN from week 7-12 while group 2 will stay on habitual diet. A flexible sigmoidoscopy will be repeated at week 12. Population: adults and adolescents between the ages of 17-65 with a mild to moderate active disease (Simple Clinical Colitis Activity Index (SCCAI) 5-10 with an endoscopic Mayo score 1-3), on an existing maintenance therapy comparing two arms. Time frame: The induction of remission phase will last 8 weeks followed by maintenance phase for a period of 24 weeks Expected outcomes and significance: The investigators anticipate that adding a novel specifically designed dietary intervention in addition to drug will lead to superior remission and mucosal healing via changes in the microbiome.
Interventions
OTHERUlcerative colitis Exclusion Diet
a limited whole food diet (UCED)
OTHERPartial enteral nutrition (PEN)
The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles.
OTHERfree diet
oral Budeosnide for 6 weeks + free diet
DRUGOral Budesonide
Oral Budesonide 9 mg
Sponsors
Wolfson Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)
Masking description
The physician
Eligibility
Sex/Gender
ALL
Age
17 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Informed consent * Established diagnosis of UC with mild to moderate active disease, 5 ≤ SCCAI ≤ 10 * Age: 17-65 years (inclusive) * Extent E1-E3 by the Montreal classification * Active colitis in the rectum or sigmoid colon on sigmoidoscopy * Stable medication use of oral 5ASA for at least 8 weeks, thiopurines, vedolizumabs, Ustekinumab or tofacitinib for at least 12 weeks
Exclusion criteria
* Severe colitis (SCCAI\>10) hospitalization for acute severe colitis (ASC) in the previous 6 months * Use of steroids in the previous 3 months * Patients treated with Anti-TNF currently or in patients who had previously failed or lost response to anti TNF * Vegans (vegetarians may enroll) * Pregnancy * Inability use of budesonide due to severe adverse events * Extraintestinal manifestations such as arthritis, spondyloarthropathy or uveitis * Presence of baseline hypoalbuminemia * Fever \>38°C * Evidence for Clostridioides difficile infection * Renal failure * Hepatitis or PSC (Primary Sclerosing Cholangitis) * Active malignancy (excluding skin BCC).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Steroid free remission | week 12 | Steroid free intention-to-treat (ITT) remission according to SCCAI\<3 at week 12 \*The Simple Clinical Colitis Activity Index (SCCAI). score ranges from 0 to 19. clinical remission will be defined according to SCCAI\<3 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Steroids free remission | week 6 | Steroid free intention-to-treat (ITT) remission according to SCCAI\<3 at week 6 \*The Simple Clinical Colitis Activity Index (SCCAI). score ranges from 0 to 19. clinical remission will be defined according to SCCAI\<3 |
| Sustained steroid free remission | week 24 | according to SCCAI\<3 at week 24 score ranges from 0 to 19. clinical remission will be defined according to SCCAI\<3 |
| Clinical response | week 12 | \*The Simple Clinical Colitis Activity Index (SCCAI). score ranges from 0 to 19 . Clinical response defined as 3-point reduction in SCCAI or remission. |
| Change in medical therapy | by week 12 | Need for additional or change in medical therapy according to the physician decision. |
| Fecal calprotectin | week 12 | Fecal calprotectin will be analyzed locally, and will be defined as median/mean change in calprotectin from baseline. |
| Endoscopic remission | week 12 | Defined as Mayo score 0 or 1. Mayo score 0 or 1 means endoscopic remission. \*The Mayo Score for ulcerative colitis disease activity provides an assessement of disease severity and can be used to monitor patients during therapy. |
Countries
Israel, Italy, Netherlands, Switzerland
Outcome results
None listed